Lipoprotein profile in breast cancer women: effect of tamoxifen treatment.
Electrophoretic lipoprotein analyses were performed in 51 patients on tamoxifen and compared with those obtained from 33 newly diagnosed breast cancer patients and with data from the group of healthy women. A statistically significant lower rate of dyslipoproteinemia has been demonstrated in tamoxifen group in comparison with untreated patients; 23.5% vs. 54.5% (p < 0.01). Comparing the results of the latter group with normal subjects there was a significantly higher frequency of dyslipoproteinemia in untreated patients, 54.5% vs. 28.9% (p < 0.05). Our findings confirmed an estrogen-like influence of tamoxifen on lipoprotein profile in postmenopausal breast cancer patients.